Literature DB >> 8020567

Involvement of gp130/interleukin-6 receptor transducing component in interleukin-11 receptor.

M Fourcin1, S Chevalier, J J Lebrun, P Kelly, A Pouplard, J Wijdenes, H Gascan.   

Abstract

The recently cloned interleukin (IL)-11 displays many biological properties in common with those reported for IL-6. In order to analyze the nature and the functionality of the IL-11 receptor we developed a proliferative assay using the human multifactor-dependent cell line TF1. We showed that a blocking monoclonal antibody GPX7 raised against the gp130/IL-6 receptor transducing subunit was also able to inhibit the IL-11-triggered TF1 line proliferation. In addition, involvement of gp130 in IL-11 signaling was demonstrated by an induction of the transducing protein phosphorylation in response to IL-11, as observed for IL-6. In contrast, the blocking monoclonal antibody B-R6, which recognized the gp80/IL-6 binding subunit failed to interfere with the IL-11 proliferative signal in the TF1 cell line. Similarly, we did not observe any competition between IL-6 and IL-11 for a putative common binding site on the cell surface. These results suggest that the IL-11 binding component is different from the gp80/IL-6 receptor. In conclusion, IL-11, along with IL-6, leukemia inhibitory factor, oncostatin M and ciliary neurotrophic factor, belongs to the same family of cytokines, using gp130 as a transducing protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8020567     DOI: 10.1002/eji.1830240143

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Evidence for the formation of a heterotrimeric complex of leukaemia inhibitory factor with its receptor subunits in solution.

Authors:  J G Zhang; C M Owczarek; L D Ward; G J Howlett; L J Fabri; B A Roberts; N A Nicola
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

Review 2.  IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.

Authors:  B E Barton
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 3.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

4.  Mediation of interleukin-11-dependent biological responses by a soluble form of the interleukin-11 receptor.

Authors:  J Karow; K R Hudson; M A Hall; A B Vernallis; J A Taylor; A Gossler; J K Heath
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

5.  Functional characterization of W147A: a high-affinity interleukin-11 antagonist.

Authors:  Nicholas Underhill-Day; Lisa A McGovern; Natalia Karpovich; Helen J Mardon; Victoria A Barton; John K Heath
Journal:  Endocrinology       Date:  2003-08       Impact factor: 4.736

6.  Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth.

Authors:  Renate Burger; Andreas Günther; Katja Klausz; Matthias Staudinger; Matthias Peipp; Eva Maria Murga Penas; Stefan Rose-John; John Wijdenes; Martin Gramatzki
Journal:  Haematologica       Date:  2016-09-22       Impact factor: 9.941

7.  Physical association of JAK1 and JAK2 tyrosine kinases with the interleukin 2 receptor beta and gamma chains.

Authors:  N Tanaka; H Asao; K Ohbo; N Ishii; T Takeshita; M Nakamura; H Sasaki; K Sugamura
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

8.  A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11.

Authors:  Marina Cardó-Vila; Amado J Zurita; Ricardo J Giordano; Jessica Sun; Roberto Rangel; Liliana Guzman-Rojas; Cristiane D Anobom; Ana P Valente; Fábio C L Almeida; Johanna Lahdenranta; Mikhail G Kolonin; Wadih Arap; Renata Pasqualini
Journal:  PLoS One       Date:  2008-10-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.